• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The new joint EAS/ESC guidelines for the management of dyslipidaemias.

作者信息

Catapano Alberico L, Chapman John, Wiklund Olov, Taskinen Marji-Riitta

机构信息

Department of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, 20133 Milano, Italy.

出版信息

Atherosclerosis. 2011 Jul;217(1):1. doi: 10.1016/j.atherosclerosis.2011.06.011. Epub 2011 Jun 30.

DOI:10.1016/j.atherosclerosis.2011.06.011
PMID:21722901
Abstract
摘要

相似文献

1
The new joint EAS/ESC guidelines for the management of dyslipidaemias.欧洲动脉粥样硬化学会（EAS）/欧洲心脏病学会（ESC）血脂异常管理联合新指南。
Atherosclerosis. 2011 Jul;217(1):1. doi: 10.1016/j.atherosclerosis.2011.06.011. Epub 2011 Jun 30.
2
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理指南 血脂异常管理特别工作组
Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028.
3
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理特别工作组
Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012.
4
[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: What is new?].[2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：有哪些新内容？]
Turk Kardiyol Dern Ars. 2017 Mar;45(2):109-112. doi: 10.5543/tkda.2017.10305.
5
Dyslipidemia therapy update: the importance of full lipid profile assessment.血脂异常治疗进展：全面血脂谱评估的重要性
Adv Ther. 2009 Jul;26(7):711-8. doi: 10.1007/s12325-009-0052-3. Epub 2009 Jul 27.
6
[The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].[2013年美国心脏病学会/美国心脏协会关于降低动脉粥样硬化性心血管风险的血脂治疗新指南：与欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理建议的比较]
G Ital Cardiol (Rome). 2014 Jan;15(1):19-20. doi: 10.1714/1394.15514.
7
New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理新指南——共识背后是否存在争议？
Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):724-7. doi: 10.1177/1741826711418946.
8
[Atherogenic dyslipidemia: a multidisciplinary consensus panel].[致动脉粥样硬化性血脂异常：多学科共识小组]
Clin Investig Arterioscler. 2013 Apr-Jun;25(2):83-91. doi: 10.1016/j.arteri.2013.03.001. Epub 2013 Jun 6.
9
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南。
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
10
[New european guidelines for dyslipidemia].[欧洲血脂异常新指南]
Rev Med Suisse. 2012 Mar 7;8(331):525-6, 528-30.

引用本文的文献

1
Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease.CD69联合EGR1在冠心病诊断中的价值分析
Exp Ther Med. 2019 Mar;17(3):2047-2052. doi: 10.3892/etm.2019.7175. Epub 2019 Jan 15.
2
Lipid levels and new-onset diabetes in a hypertensive population: the China Stroke Primary Prevention Trial.高血压人群的血脂水平与新发糖尿病：中国脑卒中一级预防试验。
Sci Rep. 2017 Aug 1;7(1):7014. doi: 10.1038/s41598-017-07355-w.
3
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
脂肪营养不良综合征的诊断与管理：多学会实践指南
J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466. Epub 2016 Oct 6.
4
Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.评估沙罗格列扎对印度糖尿病血脂异常患者安全性和有效性的观察性研究。
Indian Heart J. 2015 Jan-Feb;67(1):23-6. doi: 10.1016/j.ihj.2015.02.007. Epub 2015 Feb 26.
5
The genetics of familial hypercholesterolemia and emerging therapies.家族性高胆固醇血症的遗传学与新兴疗法
Appl Clin Genet. 2015 Jan 28;8:27-36. doi: 10.2147/TACG.S44315. eCollection 2015.
6
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.米泊美生，一种载脂蛋白B-100反义寡核苷酸，可降低不同人群高胆固醇血症患者的脂蛋白(a)水平：4项III期试验结果
Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):689-99. doi: 10.1161/ATVBAHA.114.304549. Epub 2015 Jan 22.
7
Risk factors of CVD mortality among the elderly in Beijing, 1992 - 2009: an 18-year cohort study.1992 - 2009年北京老年人心血管疾病死亡的危险因素：一项为期18年的队列研究。
Int J Environ Res Public Health. 2014 Feb 21;11(2):2193-208. doi: 10.3390/ijerph110202193.
8
Risk factors for cerebrovascular disease mortality among the elderly in Beijing: a competing risk analysis.北京老年人脑血管疾病死亡的危险因素：一项竞争风险分析。
PLoS One. 2014 Feb 4;9(2):e87884. doi: 10.1371/journal.pone.0087884. eCollection 2014.
9
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy.监测降脂药物治疗患者的血脂、酶和肌酸激酶。
Curr Cardiol Rep. 2013 Sep;15(9):397. doi: 10.1007/s11886-013-0397-8.
10
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).《欧洲临床实践心血管疾病预防指南（2012年版）》：欧洲心脏病学会及其他学会关于临床实践心血管疾病预防的第五联合工作组（由九个学会的代表及特邀专家组成）
Int J Behav Med. 2012 Dec;19(4):403-88. doi: 10.1007/s12529-012-9242-5.